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Background: Patients with the later-onset IVS4+919G>A (IVS4) Fabry mutation are known to have positive central
nervous system involvement compared with age- and sex-matched controls. This study compares central nervous
system manifestations in patients with the IVS4 mutation or classical Fabry mutations.
Methods: This was a retrospective analysis of magnetic resonance imaging (MRI) data from Taiwanese patients
enrolled in the Fabry Outcome Survey (sponsored by Shire; data extracted March 2015).
Results: Twenty-five IVS4 (19 males) and 12 (four males) classical Fabry patients underwent MRI at a median (range)
age of 60.7 (45.0–70.4) and 43.0 (18.0–61.4) years, respectively. All patients received agalsidase alfa enzyme replacement
therapy; two (16.7%) classical Fabry patients underwent MRI before treatment start. The pulvinar sign occurred in eight
(32.0%; seven males) IVS4 and six (50.0%; three males) classical Fabry patients. Infarction occurred in eight (32.0%) IVS4
and four (33.3%) classical Fabry patients. Fazekas scores of 0, 1, 2, and 3 were found for 15 (60.0%), seven (28.0%), two
(8.0%), and one (4.0%) of the IVS4 patients and for six (50.0%), four (33.3%), two (16.7%), and 0 classical Fabry patients,
respectively. Abnormal height bifurcation of the basilar artery was observed in 40.0% of IVS4 and 58.3% of classical
Fabry patients; abnormal laterality was observed in 4.0% of IVS4 and 16.7% of classical Fabry patients. Median (range)
basilar artery diameter was 2.7 (1.4–4.0) mm in IVS4 and 3.2 (2.3–4.7) mm in classical Fabry patients (P = 0.0293); vascular
stenosis was noted in 8.3% of IVS4 patients but in no classical Fabry patients.
Conclusions: A similar range of MRI findings was found for both IVS4 and classical Fabry patients. Notably, basilar artery
diameter was larger in classical Fabry patients than IVS4 patients.
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Magnetic resonance imagingBackground
Fabry disease (FD, MIM 301500) is an X-linked lyso-
somal disorder resulting from lysosomal α-galactosidase
A deficiency, which subsequently leads to the accumula-
tion of glycosphingolipids, primarily globotriaosylcera-
mide, throughout the body [1]. This multisystemic* Correspondence: hsz829@gmail.com; dmniu1111@yahoo.com.tw
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cence with symptoms including acroparesthesia, cornea
verticillata, and gastrointestinal complaints [2]. Progres-
sion to renal failure, hypertrophic cardiomyopathy, and
cerebrovascular complications occurs in later life; these
comprise the leading causes of premature death in FD [3].
Organ failure attributed to FD can reduce life expectancy
by approximately 25 years in males [4] and 15 years
in females [5]. Enzyme replacement therapy (ERT)
can slow disease progression [6] and, if started earlyle is distributed under the terms of the Creative Commons Attribution 4.0
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organ damage.
Neurological signs and symptoms are commonly
reported in FD and can start during childhood or adoles-
cence [7]. Neuropathic pain, vertigo, tinnitus, stroke,
and transient ischemic attack are some of the commonly
reported neurological features of FD [8, 9]. White matter
lesions and infarction, increased signal intensity in the
lateral pulvinar (known as the pulvinar sign), and
increased diameter and tortuosity of the basilar artery
[8, 10–12] are some of the abnormalities that have
been observed upon brain magnetic resonance im-
aging (MRI) in patients with FD. Increased diameter
of the basilar artery and presence of the pulvinar sign
are reportedly useful in FD diagnosis, particularly
when found alongside other, less specific, neurological
findings that are also known to occur in FD [10–12].
The incidence of FD ranges from 1 in 40,000 to 1 in
117,000 live births in the general population [1, 13].
There are 2 major phenotypes of FD, “classical” (type 1)
and “later-onset” (type 2) subtypes [14]. In Taiwan, the
Chinese hotspot IVS4+919G>A (IVS4) mutation occurs
at a high frequency [15, 16] and is reported to be a
pathogenic, later-onset, cardiac-specific Fabry mutation
[17]. Despite its high frequency, the pathology and
neurological complications of FD in individuals with the
later-onset IVS4 mutation currently are not well under-
stood. In our previous comparison of patients carrying
the IVS4 mutation with healthy age- and sex-matched
controls, we found a greater frequency of infarctions
(35% vs 0%; P = 0.001) and the pulvinar sign (30% vs 0%;
P = 0.002), and a greater volume of white matter hyper-
intensities (1.1583 cm3 vs 0.1354 cm3; P = 0.004) in
patients with IVS4-type FD [18]. The objective of the
current study is to retrospectively review and compare
the severity of central nervous system manifestations in
Taiwanese patients with the later-onset IVS4 mutation
or classical Fabry mutations.
Methods
Study design
This was a retrospective analysis of MRI data from
Taiwanese patients enrolled in the Fabry Outcome Sur-
vey (FOS; sponsored by Shire Human Genetic Therapies,
Inc). At the Taipei Veterans General Hospital (TVGH),
brain imaging is routinely performed for patients with
FD. The protocol for white matter (fluid-attenuated in-
version recovery [FLAIR]) and cerebral artery (MR angi-
ography) imaging has been optimized but not restricted
to the same machine; thus, patients receive similar
imaging protocols but can be randomly assigned to dif-
ferent scanners. This study analysed MRI and neuro-
logical signs and symptoms data gathered at the TVGH
along with demographics and baseline data collected inFOS for the same patients. The FOS registry collates
outcomes data from patients with confirmed FD who
are receiving, or are eligible for, ERT with agalsidase alfa.
Treated patients receive agalsidase alfa 0.2 mg/kg body
weight every other week. Inclusion criteria for this ana-
lysis were being Taiwanese, presence of the Chinese hot-
spot IVS4 mutation or classical Fabry mutations, as
confirmed by molecular analysis, and having undergone
brain MRI at any point after FD diagnosis. The data for
this analysis were extracted from the FOS database in
March 2015.
The Institutional Review Board of TVGH approved
participation in FOS and the MRI analysis, and all pa-
tients gave written informed consent before their data
were entered into the FOS database. Two board certified
neuroradiologists, who were blinded to the type of
disease, reviewed the brain MRIs from all patients by
consensus.
Brain imaging
Non-contrast MRIs were obtained on one of three
1.5-tesla or 3-tesla scanners (Signa Excite 1.5T, GE
Healthcare, Milwaukee, WI, USA; SignaHDxt 1.5T, GE
Healthcare; Discovery MR750 3.0T, GE Healthcare).
Axial spin-echo T1-weighted imaging parameters were
1.5T, 600–700/8–11/2 (TR/TE/NEX) and 3T, 360/9/1
(TR/TE/NEX). Axial FLAIR imaging parameters were
1.5T, 9000/92/2250 ms (TR/TE/TI) and 3T, 9000/145/
2250 ms (TR/TE/TI). Time-of-flight angiography param-
eters were 1.5T, 26–28/6.8 ms (TR/TE) and 3T, 25/
2.8 ms (TR/TE); flip angle 20°, voxel size 0.4 x 0.4 x
0.5 mm.
Qualitative assessment
The methods used for image analysis are described in
our previous study [18]. The presence and location of in-
farction was categorized as none, anterior circulation
alone, posterior circulation alone, or both anterior and
posterior circulation. Furthermore, high signal changes
on T1-weighted images bilaterally at the lateral pulvinar
were considered as the pulvinar sign [11].
Semi-quantitative assessment
Deep white matter hyperintensities on T2-weighted im-
ages or FLAIR sequences were graded according to the
Fazekas scale, which classifies white matter hyperintensi-
ties according to the following scoring system: 0, absent;
1, punctate foci; 2, beginning of confluence of foci; and
3, large confluent areas [19].
The degree of elongation and tortuosity of the basilar
artery were evaluated using Smoker’s criteria [20]
according to the height of basilar artery bifurcation and
its most lateral position. The scale used to categorize the
height of basilar artery bifurcation was as follows: 0, at
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tern; 2, at the level of the floor of the third ventricle; and
3, indenting and elevating the floor of the third ventricle.
The most lateral position of the basilar artery was
graded as follows: 0, midline throughout; 1, medial to
lateral margins of the clivus or dorsum sellae; 2, lateral
to lateral margins of the clivus or dorsum sellae; and 3,
situated in the cerebellopontine angle cistern.
Quantitative assessment
The diameter of the basilar artery was measured on a
workstation (AZE Virtual Place Plus, AZE Ltd., Tokyo,
Japan) by an observer who was blinded to all clinical in-
formation. A line was drawn perpendicular to the middle
portion of the basilar artery on the sagittal view of a
three-dimensional time-of-flight magnetic resonance
angiogram at the maximum intensity projection. The ob-
server then recorded the diameter as the full width at
half maximum of this middle segment. Vascular stenosis
was identified when the diameter of the basilar artery
was less than 2 mm or appeared hypoplastic.
Neurological signs and symptoms
The prevalence of neurological signs and symptoms was
obtained from the FOS database and compared between
patients with IVS4 or classical Fabry mutations and MRI
data. The neurological signs and symptoms analysed in-
clude stroke, sudden onset of numbness or weakness in
the extremities, asymmetric facial expression, dysarthria,
sudden onset of blurred vision or diplopia, depression,
emotional or personality changes, forgetfulness, tinnitus,
and vertigo.
Statistical analysis
The statistical analysis was performed using SAS soft-
ware, version 9.2 (SAS Institute Inc., Cary, NC, USA).
Descriptive statistics were calculated for demographic,
MRI, and signs and symptoms data. For continuous vari-
ables, 95% confidence intervals for means were calcu-
lated using t-distribution, and for binary variables exact
(Clopper-Pearson) 95% confidence intervals were
computed. Differences between IVS4 versus classical
Fabry mutations in binary outcome variables were
assessed using Fisher’s exact test. Differences in continu-
ous variables between patients with IVS4 versus classical
Fabry mutations were evaluated using the Wilcoxon
rank-sum test, either exact (when computationally feas-
ible) or normal approximation. Potential associations
between mutation type and presence of neurological
signs and symptoms were examined using Fisher’s exact
test; estimated odds ratios together with 95% exact
confidence limits are reported. All statistical analyses are
exploratory and the results of the statistical tests
(p-values) are interpreted descriptively, as hypothesisgeneration rather than hypothesis testing. The level of
significance was set to 5% without any multiplicity ad-
justment. P-values above the significance level of 5% are
not considered as confirmation of no difference between
the groups, and p-values below 5% are not considered as
confirmation of a difference between the groups.Results
A total of 37 Taiwanese patients registered in FOS had
brain MRI data; of these, twice as many had the IVS4
mutation (67.6%) than classical Fabry mutations (32.4%).
The majority of IVS4 patients were male (76.0%)
whereas females comprised the majority of classical
Fabry patients (67.0%; Table 1). Median age at symptom
onset, diagnosis, FOS entry, and MRI assessment was
greater for IVS4 patients than classical Fabry patients
(Table 1). All patients received ERT with agalsidase alfa;
all IVS4 patients and 83.3% of classical Fabry patients
underwent brain MRI after ERT initiation (Table 1).
Brain MRI in both IVS4 and classical Fabry patients
revealed infarction, deep matter hyperintensities (Fig. 1,
Fig. 2), and the pulvinar sign (Fig. 1, Fig. 3). Overall, in-
farcts were observed in similar proportions of IVS4 and
classical Fabry patients (32.0% and 33.3%, respectively;
Table 2), although with some differences in the site of
occurrence. Anterior circulation stroke alone and poster-
ior circulation stroke alone each occurred in 8.0% of
IVS4 patients, and both anterior and posterior circula-
tion stroke occurred in 16.0% of IVS4 patients. Posterior
circulation stroke alone was not observed in classical
Fabry patients; instead, anterior circulation stroke alone
and both anterior and posterior circulation stroke each
occurred in 16.7% of classical Fabry patients (Table 2).
Hemorrhage was noted in MRIs from 16.7% of classical
Fabry patients, but not in any MRIs from IVS4 patients
(Table 2).
Fazekas scores for deep white matter hyperintensities
were assigned for 100.0% of both IVS4 and classical
Fabry patients. In each group, the largest proportion of
patients was assigned a Fazekas score of 0 (60.0% for
IVS4 and 50.0% for classical Fabry patients), followed by
scores of 1 (28.0% and 33.3%), 2 (8.0% and 16.7%), and 3
(4.0% IVS4 patients only; Table 2). The pulvinar sign
was observed in a greater proportion of classical Fabry
patients (50.0%) than IVS4 patients (32.0%; Table 2).
Abnormal height bifurcation of the basilar artery was
observed in 40.0% of IVS4 and 58.3% of classical Fabry
patients (at the third ventricular floor in all IVS4 and
50.0% of classical Fabry patients, and indenting and ele-
vating the third ventricular floor in 8.3% of classical
Fabry patients; Table 2). Abnormal laterality of the basi-
lar artery was observed in 4.0% of IVS4 and 16.7% of
classical Fabry patients (lateral to lateral margins of the
Fig. 1 A middle-aged man with classical-type Fabry disease who
suffered from chronic renal disease. a Brain magnetic resonance axial
T2 fluid-attention inversion recovery reveals an old lacunar infarct at the
right centrum semiovale (arrow) and deep white matter hyperintensities
(arrowheads). b Axial T1-weighted image reveals high signal changes at
the bilateral posterior thalamus (arrows), the pulvinar sign. c The diameter
at the middle segment of the basilar artery (lines) was measured as
4.0 mm on a three-dimensional time-of-flight magnetic
resonance angiogram
Table 1 Demographic characteristics of Taiwanese patients with
MRI data registered in FOS as of March 2014
Characteristic IVS4 mutation n = 25 Classical Fabry
mutations n = 12
P-value
Sex, n (%)
Male 19 (76.0) 4 (33.0) 0.0274a
95% CI 0.55-0.91 0.10-0.65
Female 6 (24.0) 8 (67.0)
Age at symptom
onset, yearsc
Mean (SD) 50.3 (7.8) 9.5 (2.0)
95% CI 46.2-54.5 8.1-10.9
Median (range) 48.0 (38.0-65.0) 10.0 (6.0-12.0) <0.0001b
Age at diagnosis,
years
Mean (SD) 57.6 (6.9) 39.8 (14.5)
95% CI 54.7-60.4 30.6-49.1
Median (range) 59.0 (42.0-67.0) 40.0 14.0-60.0) 0.0001b
Age at FOS
entry, years
Mean (SD) 59.7 (6.7) 42.4 (14.1)
95% CI 56.9-62.5 33.4-51.4
Median (range) 60.3 (44.8-69.7) 43.3 (17.4-61.2) <0.0001b
Received ERT, n
Yes 25 12 NA
95% CI 0.86-1.00 0.74-1.00
Age at treatment
start, years
Mean (SD) 58.6 (6.8) 40.9 (14.5)
95% CI 55.8-61.5 31.7-50.1
Median (range) 59.7 (44.1-68.3) 40.9 (14.9-61.3) 0.0001b
MRI after treatment
initiation, n (%)
Yes 25 (100.0) 10 (83.3) 0.0991a
95% CI 0.86-1.00 0.52-0.98
Age at MRI
assessment, years
Mean (SD) 60.0 (6.8) 42.6 (14.3)
95% CI 57.2-62.8 33.6-51.7
Median (range) 60.7 (45.0-70.4) 43.0 (18.0-61.4) 0.0001b
ERT, enzyme replacement therapy; FOS, Fabry Outcome Survey; IVS4, IVS4+
919G>A; MRI, magnetic resonance imaging; NA, not available
aFisher’s exact test
bWilcoxon rank-sum test
cData missing from 9 IVS4 (n = 16) and 2 classical FD (n = 10) patients
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erality; Table 2).
The median diameter of the middle segment of the
basilar artery was larger in classical Fabry patients than
it was in IVS4 patients (3.2 mm vs 2.7 mm; P = 0.0293;
Table 2). Vascular stenosis of the basilar artery wasnoted in 8.3% of IVS4 patients but in none of the clas-
sical Fabry patients (Table 2).
Of the IVS4 patients who did not demonstrate MRI
evidence of infarction, eight of 17 (47.1%) presented with
one or more non-specific neurological symptoms, in-
cluding numbness/weakness (n = 1), depression (n = 1),
forgetfulness (n = 2), tinnitus (n = 2), vertigo (n = 4;
Table 3). For IVS4 patients with MRI evidence of infarc-
tion, six of eight (75.0%) presented with one or more
non-specific neurological symptoms, including numb-
ness/weakness (n = 2), asymmetric face (n = 1), blurred
vision/diplopia (n = 1), emotional change (n = 2), person-
ality change (n = 1), forgetfulness (n = 4), tinnitus (n = 1),
and vertigo (n = 1), and two patients were clinically si-
lent. Of the classical Fabry patients who showed no MRI
evidence of infarction, four of eight (50.0%) reported
neurological complaints, including numbness/weakness
(n = 1), emotional change (n = 3), forgetfulness (n = 1),
and tinnitus (n = 1). Of the four classical Fabry patients
with MRI evidence of infarction, two reported symptoms
of numbness/weakness, one of whom also reported
Fig. 2 A middle-aged female patient with IVS4+919G>A-type Fabry disease who suffered from hypertrophic cardiomyopathy and sudden onset of
limb weakness. a Brain magnetic resonance axial T2 fluid-attention inversion recovery shows old lacunar infarct at the left corona radiata (arrow) and
increased deep white matter hyperintensities (arrowhead). b The diameter at the middle segment of the basilar artery was measured as 3.3 mm on a
three-dimensional time-of-flight magnetic resonance angiogram
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were clinically silent. No statistically significant associa-
tions were found between the type of mutation (IVS4 or
classical Fabry) and any neurological sign or symptom.
Discussion
Fabry disease is classified as the classical phenotype (type 1)
or the later-onset phenotype (type 2), which tends to haveFig. 3 A middle-aged female patient with IVS4+919G>A-type Fabry
disease with hypertrophic cardiomyopathy. Brain magnetic resonance axial
T1-weighted image reveals the pulvinar sign with high signal changes at
the bilateral posterior thalamus (arrows)mutation-specific renal or cardiac damage. Classical FD is
characterized by frequent central nervous system involve-
ment, which may be caused by the deposition of glyco-
sphingolipids in cerebrovascular endothelial cells, a
consequence of cardiogenic embolism from cardiomyop-
athy, valvular heart disease, ischemic heart disease, and/or
arrhythmias [21–24]. Cardiac involvement is already
acknowledged in later-onset IVS4 FD, but the degree of
extra-cardiac involvement is still not well known. Brain
MRI findings in our previous study demonstrated a greater
degree of neurological involvement in patients with IVS4
FD compared with age- and sex-matched healthy controls
[18]. In this study, we showed that patients carrying the
later-onset IVS4 mutation had similar central nervous sys-
tem involvement to that of classical Fabry patients, but with
a lower degree of basilar artery dilatation.
In this comparison between patients with IVS4 and clas-
sical FD, the prevalence of infarction was similar in each
group (32.0% for IVS4 patients and 33.3% for classical
Fabry patients). The incidence of stroke found in our pa-
tients is much higher than in the general population [25],
but similar to the results of other studies on FD [21, 22].
Vertebrobasilar dolichoectasia is thought to be an early
and frequent sign of classical FD [26], and tends to be
more frequently observed in elderly or male FD patients
[18, 26]. In our study, median basilar artery diameter
was larger in classical Fabry patients than IVS4 patients,
despite the IVS4 group containing more males and
having an older median age than the classical Fabry
group. This may reflect less basilar artery involvement in
IVS4 patients than classical Fabry patients. The mechan-
ism of dolichoectasia is still not completely understood.
In contrast with the histology of classical FD vasculopa-
thy, and despite significant globotriaosylceramide accu-
mulation in cardiomyocytes, no endothelial deposition





mutations n = 12
P-value
MRI findings
Pulvinar sign, n (%) 8 (32.0) 6 (50.0) 0.4701a
95% CI 0.15-0.54 0.21-0.79
Infarct, n (%) 8 (32.0) 4 (33.3) 0.6759b
95% CI 0.15-0.54 0.10-0.65
Anterior circulation
stroke







4 (16.0) 2 (16.7)
None of them 17 (68.0) 8 (66.7)
Hemorrhage
(microbleeds), n (%)
0 2 (16.7) 0.0991a
Fazekas score, n 25 12 0.7378a
0: No or a single
punctate WM lesion
15 (60.0) 6 (50.0)
1: Multiple punctate
WM lesions
7 (28.0) 4 (33.3)
2: Beginning of lesion
confluence




Height bifurcation of the
BA, n
25 12 0.4276*
0: At or below the
dorsum sellae
6 (24.0) 2 (16.7)
1: Within the suprasellar
cistern
9 (36.0) 3 (25.0)
2: At the third ventricle
floor







10 (40.0) 7 (58.3)
Laterality of the BA, n 25 12 0.3652a
0: Midline throughout 12 (48.0) 4 (33.3)
1: Medial to lateral
margins of clivus or
dorsum sellae
12 (48.0) 6 (50.0)
2: Lateral to lateral
margins of clivus or
dorsum sellae





Abnormal laterality 1 (4.0) 2 (16.7) 0.2407a
95% CI 0.00-0.20 0.02-0.48
Table 2 MRI and MRA findings in patients with IVS4 versus
classical Fabry mutations (Continued)
MRA findings
BA diameter, mm
Mean (SD) 2.7 (0.6) 3.3 (0.7)
95% CI 2.5-3.0 2.9-3.8
Median (range) 2.7 (1.4-4.0) 3.2 (2.3-4.7) 0.0293b
Vascular stenosis/BA
hypoplasia, nc (%)
2 (8.3) 0 0.5429a
95% CI 0.01-0.27 0.74-1.00
BA, basilar artery; IVS4, IVS4+919G>A; MRA, magnetic resonance angiography;
MRI, magnetic resonance imaging; WM, white matter
aFisher’s exact test
bWilcoxon rank-sum test
cData missing from one IVS4 patient, thus n = 24
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cardial biopsy study [17], or in other reports on later-
onset, cardiac-specific variants [27–29]. These findings
support the theory that later-onset FD should be consid-
ered a unique entity that is different from classical FD,
owing to the primary involvement of cardiomyocytes
instead of endothelial cells. Furthermore, later-onset FD
presentation and course might not be the same as typic-
ally observed in classical FD. Thus, long-term follow-up
studies of IVS4 FD are needed for a more thorough
understanding of the progression of this disease.
White matter hyperintensities, which are thought to
be related to small vessel disease and secondary to the
severity of perfusion dysfunction in FD cerebral vascu-
lopathy, were quite similar in frequency between the two
groups [30]. Furthermore, the pulvinar sign, which may
be caused by regional hyperperfusion and reflect associ-
ated subtle dystrophic calcifications and end-organ dam-
age [10, 11], was found in 32% and 50% of patients in
the IVS4 and classical FD groups. This might provide
supportive evidence of CNS involvement in IVS4 FD.
However, the median age of the IVS4 group is higher
than the classical Fabry group and patient numbers are
too small to provide a solid conclusion; thus, further
investigation with a larger population is necessary.
In addition to cerebrovascular events, cognitive dys-
function, although mild in nature, and depression are
already known in FD patients [31]. In the current ana-
lysis, in terms of neurological presentations, IVS4 and
classical Fabry patients shared several similarities. First,
as previously mentioned, the observed incidence of
infarction was similar in the two groups. Silent infarcts
are commonly noted events in FD, but the frequency of
silent brain infarcts in FD is still not yet known [32].
Second, there was a high prevalence of non-specific
signs and symptoms or silent infarcts in both groups
(62.5% in IVS4 patients and 50.0% in classical Fabry


















mutations n = 4
Any neurological
manifestation
14 (56.0) 6 (50.0) 1.27 (0.26-6.28); 1.0000 8 (47.1) 4 (50.0) 6 (75.0) 2 (50.0)
Stroke/minor stroke 1 (4.0) 1 (8.3) 0.46 (0.01-39.22); 1.0000 0 0 1 (12.5) 1 (25.0)
Numbness/weakness 3 (12.0) 3 (25.0) 0.41 (0.05-3.74); 0.3666 1 (5.9) 1 (12.5) 2 (25.0) 2 (50.0)
Asymmetric face 1 (4.0) 0 (0.03-NA); 1.0000 0 0 1 (12.5) 0
Dysarthria 0 1 (8.3) (0.03-NA); 0.3243 0 0 0 1 (25.0)
Blurred vision/diplopia 1 (4.0) 0 (0.03-NA); 1.0000 0 0 1 (12.5) 0
Depression 1 (4.0) 0 (0.03-NA); 1.0000 1 (5.9) 0 0 0
Emotional change 2 (8.0) 3 (25.0) 0.26 (0.02-2.79); 0.3035 0 3 (37.5) 2 (25.0) 0
Personality change 1 (4.0) 0 (0.03-NA); 1.0000 0 0 1 (12.5) 0
Forgetfulness 6 (24.0) 1 (8.3) 3.47 (0.34-174.06); 0.3891 2 (11.8) 1 (12.5) 4 (50.0) 0
Tinnitus 3 (12.0) 1 (8.3) 1.50 (0.10-85.80); 1.0000 2 (11.8) 1 (12.5) 1 (12.5) 0
Vertigo 5 (20.0) 0 (0.62-NA); 0.1521 4 (23.5) 0 1 (12.5) 0
IVS4, IVS4+919G>A; MRI, magnetic resonance imaging; NA, not available
Lee et al. BMC Neurology  (2017) 17:25 Page 7 of 8patients). These findings indicate that regular neuro-
logical and neuroimaging assessments are important and
should be recommended for patients with the cardiac
IVS4 mutation.
This study had some limitations that should be
addressed. First, the FOS registry is not designed to con-
firm differences between groups of patients and because
of the small group sizes the statistical tests lacked power
and robustness, restricting the analyses to the descriptive
level. Second, differences were observed in age at MRI
assessment and in the proportion of females in each
group; thus, as the incidence of stroke among patients
with FD increases with age [21], the results herein must
be interpreted with caution. A large longitudinal cohort
comparison is needed to effectively evaluate neurological
differences between patients with IVS4 and classical
Fabry mutations.
Conclusions
In conclusion, the range of abnormalities found on brain
MRI for classical Fabry patients is consistent with previ-
ous observations and also is similar in patients with the
IVS4 mutation. Patients with the IVS4 mutation experi-
ence similar neurological signs and symptoms to
patients with classical Fabry mutations.
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